Article Figures & Data
Figures
- Figure 1.
Evolution of percentage and absolute number of CD8+CD28– T cells during therapy with abatacept.
- Figure 2.
Correlations of variations of T cell subpopulation percentages with variation of the Disease Activity Score (DAS28) during therapy with abatacept.
Tables
- Table 1.
Patient characteristics at baseline. Medians, except for HAQ score, are interquartile range (25th–75th percentile).
Characteristic Patients (n = 20) Age, median, yrs 55 (47–63) Men 4 Women 16 Disease duration at inclusion, median 12.5 (9–20.75) No. previous DMARD treatments, median 4 (2.75–5) No. previous anti-TNF agents, median 2 (1.75–3) Prior rituximab treatments 6 Concomitant DMARD treatments Methotrexate 18 Other DMARD 0 None 2 Rheumatoid factor positivity (%) 14 (70) DAS28 (CRP) median 5.53 (5.05–6.35) HAQ score median 1.25 (0.875–1.375) -
DMARD: disease-modifying antirheumatic drugs; DAS28 (CRP): Disease Activity Score in 28 joints (C-reactive protein); HAQ: Health Assessment Questionnaire; TNF: tumor necrosis factor.
-
- Table 2.
Variations of percentages and absolute numbers of T cell subsets in patients with rheumatoid arthritis after treatment with abatacept. Numbers in 2nd line of each box are absolute numbers (cell/μl).
Lymphocyte Subtype Baseline 48 Weeks CD3+CD4+ % of total lymphocyte 59.2 (46.9–70.3) 63.3 (51.1–70.4) 0.472 No. cells 749 (322–1773) 851 (328–1438) 0.937 CD3+CD4+ naïve % of total CD3+CD4+ 37.2 (22.1–38.9) 33.1 (21.8–36.8) 0.556 No. cells 216 (135–445) 325 (148–446) 0.790 CD3+CD4+ CM % of total CD3+CD4+ 41.1 (34.5–44.6) 54.1 (42.1–57.2) 0.061 No. cells 292 (200–411) 466 (316–702) 0.473 CD3+CD4+ EM % of total CD3+CD4+ 20.3 (14.7–25.1) 14.7 (10.5–17.6) 0.519 No. cells 149 (113–227) 124 (87–153) 0.399 CD3+CD4+ TDEM % of total CD3+CD4+ 1.25 (0.6–2.5) 0.8 (0.5–1.6) 0.270 No. cells 12 (5–22) 6 (4–12) 0.449 CD3+CD4+ EFF TOT % of total CD3+CD4+ 21.5 (15.4–31.2) 16 (10.8–18.8) 0.352 No. cells 163 (129–261) 135 (93–159) 0.296 CD3+CD4+CD28+ % of total CD3+CD4+ 95.2 (84.9–95.9) 96.9 (90.3–98.6) 0.349 No. cells 680 (446–879) 825 (510–1162) 0.954 CD3+CD4+CD28– % of total CD3+CD4+ 4.8 (4.1–15.1) 3.0 (1.4–9.7) 0.349 No. cells 49 (32–75) 20 (15–27) 0.257 CD3+CD8+ % of total lymphocyte 20.4 (13.0–28.6) 21.4 (13.0–27.9) 0.941 No. cells 188 (128–581) 288 (79–502) 0.927 CD3+CD8+ naïve % of total CD3+CD8+ 18.6 (12.6–31.8) 27.2 (20.6–35.0) 0.342 No. cells 48 (23–91) 88 (29–160) 0.304 CD3+CD8+ CM % of total CD3+CD8+ 11.5 (7.1–13.7) 22.3 (15.6–32.5) 0.002 No. cells 29 (15–43) 44 (17–117) 0.128 CD3+CD8+ EM % of total CD3+CD8+ 29.9 (23.2–42.2) 26.8 (20.9–33.7) 0.377 No. cells 81 (57–121) 64 (37–86) 0.276 CD3+CD8+ TDEM % of total CD3+CD8+ 32.0 (20.4–41.3) 21.8 (9.7–25.7) 0.033 No. cells 72 (52–112) 26 (17–48) 0.132 CD3+CD8+ EFF TOT % of total CD3+CD8+ 68.7 (54.5–78.6) 49.3 (31.4–58.8) 0.040 No. cells 170 (108–234) 85 (61–132) 0.138 CD3+CD8+CD28+ % of total CD3+CD8+ 61.3 (37.7–75.1) 77.6 (74.0–87.6) 0.009 No. cells 124 (85–267) 249 (99–400) 0.528 CD3+CD8+CD28– 38.7 (24.9–62.3) 22.3 (12.1–25.9) 0.008 No. cells 109 (85–145) 32 (30–41) 0.055
